Table 2.
Results
| Summary of results | Ceftolozane/tazobactam + metronidazole | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam |
|---|---|---|---|
| Total costs per patient | $44,226 | $44,811 | -$585 |
| Total life years per patient (undiscounted) | 21.75 | 21.50 | 0.25 |
| Total QALYs per patient (undiscounted) | 18.49 | 18.27 | 0.22 |
| Total QALYs per patient (discounted) | 12.85 | 12.70 | 0.15 |
| Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved) | – | – | Dominant |
| Hospitalization days saved per-patient | – | – | 0.63 |
| Distribution of patients based on empiric treatment | |||
| Resistant to initial therapy (%) | 35.2 | 48.8 | – |
| Susceptible to initial therapy (%) | 64.8 | 51.2 | – |
| Costs | |||
| Hospital costs per patient | $15,468 | $17,069 | -$1601 |
| Drug costs per patient | $818 | $196 | $622 |
| Lifetime health care expenditure per patient | $27,940 | $27,546 | $394 |
QALY Quality Adjusted Life Year, IAAT Initial appropriate antibiotic therapy, IIAT Initial inappropriate antibiotic therapy